top of page

IPD'S DRUG & CLINICAL REVIEW

THE PREMIER PODCAST FOR DRUG INTELLIGENCE & MANAGEMENT STRATEGY

SAMPLE EPISODES

Limited Distribution Drugs 101.jpg

LIMITED DISTRIBUTION DRUGS 101

​

Our Executive Clinical Pharmacy talk through the basics of limited distribution drugs and how they affect the marketplace in terms of market access, payer reimbursement, patient care, and drug development.

 

Topics included in this episode:

  • Overview and Basic Definitions of Limited Distribution Drugs and their Networks

  • Pharmacy Motivations for Carrying LDDs

  • Independent Retail Pharmacies 

  • Hospital Perspectives for Providing LDDs

  • Payer Implications for Reimbursing for LDDs

  • Patient Implications for Receiving LDDs

  • Manufacturer Motivations for Developing LDDs

 

SEE MORE

Maximum Revenue Capture.jpg

PROVIDER STRATEGIES FOR MAXIMUM REVENUE CAPTURE

​

Our Executive Clinical Pharmacy team talks through strategies for maximum revenue capture at a time when hospitals are trying to keep up with COVID-19 related admissions, while seeing less revenue coming in from elective procedures and changes to the 340B program are looming.

​

Topics included in this episode:

  • Revenue Capture Strategies

    • Pharmacy Teams 

    • Revenue Cycle Management Teams 

  • 340B Program Background

    • Pricing and Margin Implications 

    • Recent Changes 

    • Pass-through and Non-pass-through

    • Biosimilars 

    • Drugs with No ASP Pricing

    • Exemptions

    • Litigation 

  • Potential Changes for 2021 

 

SEE MORE

Limited Distribution Drugs 2.jpg

LIMITED DISTRIBUTION DRUGS PART 2

​

Our Executive Clinical Pharmacy is back to add more insight on limited distribution drugs and their networks. As the specialty drug landscape has expanded, payers and providers have struggled to stay up to date on shifting limited distribution networks, making it harder to provide these critical medicines to patients. IPD's team discusses this complexity and why it's important to track limited distribution networks.

 

Topics included in this episode:

  • Understanding Limited Distribution Networks and Why they Exist

  • Specialty Pharmacies 

  • Manufacturers and Specialty Drug Launches

  • Tracking Limited Distribution Networks

  • Limited Networks versus Specialty Drug Distributors

 

SEE MORE

Patient Financial Assistance Programs 101.jpg

PATIENT FINANCIAL ASSISTANCE PROGRAMS 101

​

Our Executive Clinical Pharmacy team talks through the basics of patient financial assistance programs and their impacts on the healthcare space.

 

Topics included in this episode:

  • Overview and Basic Definitions of Patient Financial Assistance Programs

  • Coupons or Copay Programs

  • Free-Trial Programs

  • Bridge Programs

  • Patient Assistance Programs

  • Payer Strategies

  • Accumulator and Maximizer Programs

  • Program Impacts on Payers

  • Regulatory Implications of These Programs
     

SEE MORE

​

GettyImages-1149211725.jpg

THE GROWING CLASS OF COMPLEMENT INHIBITORS​

​

Our Executive Clinical Pharmacy team talks through the complement inhibitor drug class and pipeline.

 

Topics included in this episode:

  • Overview and Basic Definitions of Complement Inhibitors

  • Complement Inhibitor Examples

  • Current Approvals

  • Side Effects

  • Current Complement Inhibitor Pipeline

  • Complement Inhibitor Class Management

  • Manufacturer Challenges

  • Implications and Final Notes

​

SEE MORE

​

Coronavirus1018.png

COVID-19 PUBLIC UPDATES

​

IPD Analytics has released four publicly available podcasts on COVID-19. In each episode, Leslie Fish, R.Ph, Pharm.D. and Julee Oh, Pharm.D. discuss the most recent news on the coronavirus, including:

  • National and Global Status

  • Vaccine Status

  • Current Treatment Options

    • Emergency Use Authorization

    • Clinical Trial Updates

    • Dosing and Administration

    • Warnings and Precautions

    • Availability

  • Manufacturer and Clinical Trial Impacts

  • Stakeholder Impacts

​

SEE MORE

May 18th, 2020 Update

April 27th, 2020 Update

March 31st, 2020 Update

March 19th, 2020 Update

medicalbilling3.jpg

  • Brand Pricing Terms and Acronyms

    • WAC

    • AWP

    • U&C

    • PBM

  • Brand Pricing Differences Based on Dispensing Method

    • Retail

    • Mail Order

    • Specialty

  • Spread Pricing

  • Generic Pricing Terms and Acronyms

    • Authorized Generic

    • Authorized Biologic

    • MAC

    • Preferred Pharmacy Networks

  • MAC Lists 

  • NDC Codes 

  • Medically Covered Drugs 

  • Methodologies for Medical Drug Reimbursement 

​

SEE MORE 

Our Executive Clinical Pharmacy Team discusses the basics of generic and brand drug pricing and reimbursement, covering:

DRUG PRICING AND REIMBURSEMENT 101

MoneyandPills3.jpg

UNDERSTANDING 505(b)2s

Our Executive Clinical Pharmacy Team discusses 505(b)(2) products and how they compete in the marketplace alongside brand and generic drugs, tackling pricing, market access, and stakeholder implications. 

Specific topics included in this episode:​

  • Background on Approval Pathways

  • 505(b)(2) Pathway

  • Interchangeability

  • Potential Barriers to Uptake

  • Payer Implications

  • Provider Implications

  • Manufacturer Motivations for 505(b)(2) Pathway

  • Coding and Reimbursement

  • Manufacturer Pricing and Formulary Access Considerations

  • Development Considerations

  • Prescriber Pushback

​

SEE MORE

Formulary management of HIV and Hep C

INFECTIOUS DISEASES: HIV AND HEPATITIS C
MANAGEMENT STRATEGY

Our Executive Clinical Pharmacy team discusses the drug pipeline and market landscape for HIV and Hepatitis C, including:

  • HIV:

    • Integrase Strand Transfer Inhibitors (INSTIs) 

    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 

    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

    • Protease Inhibitors

    • Two and Three Tablet Regimens 

    • Single Tablet Regimens 

    • New Guidelines for Recommended Regimens for First-line ART 

    • HIV Pipeline Drugs 

    • 505(b)(2)s 

    • Current Successful Management Strategies

    • Truvada and Descovy for PrEP 

  • Hepatitis C:

    • Recent Key Events 

    • Management Strategies 

 

SEE MORE

​

​

iStock-597940514_edited.jpg

MANUFACTURER LIFE-CYCLE MANAGEMENT STRATEGIES

Our Executive Clinical Pharmacy team explains manufacturer life-cycle management strategies, including specific examples of successes and failures, including:

  • Additional indications

  • New formulations

  • Next generation products

  • Different strengths

  • Bundling

  • Brand over generic strategies

  • Reimbursement incentives and coding strategies

  • Distribution channels

  • Co-pay assistance programs

  • Strategic partnerships

  • Authorized generics

​

SEE MORE 

pharmacy6.jpg

UNDERSTANDING AUTHORIZED GENERICS 

Our Executive Clinical Pharmacy Team discusses Authorized Generics (AGs) and their impacts across the marketplace, including:

  • Differences between AGs and traditional generic drugs

  • Manufacturer motivations for launching AGs

  • Examples of current AGs, positioning tactics, and potential launches

  • Impact on price erosion and uptake

  • Forecasting implications

  • Payer considerations for various lines of business

  • And more
     

SEE MORE

HospitalAdmin5.jpg

AN INSIDE LOOK AT FORMULARY MANAGEMENT AND P&T COMMITTEES

IPD experts take you through the basics of how P&T Committees work to plan their formularies, including:

  • P&T Committee goals, members, and purpose

  • Clinical and financial reviews

  • Formulary tiering

  • Payer formulary planning trends

  • Manufacturer timing and communication strategies for formulary inclusion

​

SEE MORE

branddrug.jpg

SKINNY LABELS AND OFF-LABEL UTILIZATION

Our clinical pharmacists and and former Federal Circuit Clerks take you through the basics of skinny labels and off-label drug use, including:

  • Definition and motivations behind skinny labels

  • Examples of skinny labels in the market

  • Small molecule drugs vs. biosimilars

  • Payer, provider, manufacturer, retailer, and patient implications

  • Off-label use regulation

 

SEE MORE

Find out how to access all of our podcast episodes!

bottom of page